JAY RAVAL

Jan 9, 2025 | digitalcommons.library.tmc.edu | Moisés Huamán |JAY RAVAL |James Paxton |Giselle Mosnaim

BACKGROUND: COVID-19 convalescent plasma (CCP) is an important therapeutic option for outpatients at high risk of hospitalization from SARS-CoV-2 infection. We assessed the safety of outpatient CCP transfusions administered during clinical trials. STUDY DESIGN AND METHODS: We analyzed data pertaining to transfusion-related reactions from two randomized controlled trials in the U.S. that evaluated the efficacy of CCP versus control plasma in various ambulatory settings.

Feb 5, 2024 | digitalrepository.unm.edu | Moisés Huamán |JAY RAVAL |James Paxton |Giselle Mosnaim

BACKGROUND: COVID-19 convalescent plasma (CCP) is an important therapeutic option for outpatients at high risk of hospitalization from SARS-CoV-2 infection. We assessed the safety of outpatient CCP transfusions administered during clinical trials. STUDY DESIGN AND METHODS: We analyzed data pertaining to transfusion-related reactions from two randomized controlled trials in the U.S. that evaluated the efficacy of CCP versus control plasma in various ambulatory settings.

Aug 3, 2023 | onlinelibrary.wiley.com | Moisés Huamán |JAY RAVAL |James Paxton |Giselle Mosnaim

2.2 Study design Adverse events were graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events, version 5.0. Participants were monitored throughout the trial for transfusion-related serious adverse events manifesting as severe transfusion reactions, acute respiratory distress syndrome, or adverse events of grade 3 or 4. An independent medical monitor who was unaware of trial-group assignments evaluated serious adverse events.